APA (7th ed.) Citation

Garg, M., Zhao, F., Lee, J., Sparano, J., Palefsky, J., Henry, D., . . . Kachnic, L. (2016). Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045). International Journal of Radiation Oncology, Biology, Physics, 96, S106. https://doi.org/10.1016/j.ijrobp.2016.06.262

Chicago Style (17th ed.) Citation

Garg, M.K, et al. "Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)." International Journal of Radiation Oncology, Biology, Physics 96 (2016): S106. https://doi.org/10.1016/j.ijrobp.2016.06.262.

MLA (9th ed.) Citation

Garg, M.K, et al. "Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045)." International Journal of Radiation Oncology, Biology, Physics, vol. 96, 2016, p. S106, https://doi.org/10.1016/j.ijrobp.2016.06.262.